Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD
(Thomson Reuters ONE) -
Nycomed /
Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Companies to co-market Easyhaler® combination products in major European
markets
* Nycomed to market Easyhaler® products in MENA under exclusive licensing
agreement
* Significant strengthening of Nycomed's fast-growing Respiratory portfolio
Nycomed announced today that it has entered into a collaboration agreement with
Orion Corporation (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the co-marketing of
Easyhaler® combination products for the treatment of asthma and COPD in the
major European countries and an exclusive license and distribution arrangement
for the Middle East and North Africa region (MENA). Both companies will
commercialise Easyhaler combination products under their own brands accompanied
by the Easyhaler umbrella brand.
The agreement covers Orion's new Easyhaler combination products for treatment of
asthma and COPD (chronic obstructive pulmonary disease). Orion is developing a
budesonide-formoterol formulation that combines budesonide as an anti-
inflammatory agent and formoterol as a long-acting bronchodilator. In addition,
Orion has another Easyhaler® research programme in progress to develop a
fluticasone-salmeterol formulation. In this formulation fluticasone acts as an
anti-inflammatory agent and salmeterol acts as a long-acting bronchodilator.
Both these combination products are included in the co-marketing agreement.
Respiratory is a key strategic area for Nycomed, including the COPD treatment
Daxas® (roflumilast), Alvesco® (ciclesonide) for asthma, and Omnaris®
(ciclesonide) for allergic rhinitis. The collaboration with Nycomed reinforces
Orion's presence throughout Europe and is in line with Orion's strategy to
strengthen its marketing position in Europe and the sales coverage through
partnerships. The co-marketing area - in which both companies present their own
product brands under the Easyhaler umbrella brand - covers the major European
countries including Austria, the Benelux countries, France, Germany, Greece,
Italy, Poland, Portugal, Spain and Switzerland. Orion will retain exclusive
marketing rights for the Nordic countries, U.K. and Eastern Europe where the
company is currently promoting single molecule Easyhaler products. Orion will
exclusively manufacture the Easyhaler combination products covered by the
agreement.
Dr. Liisa Hurme, Senior Vice President of Orion's Proprietary Products division,
commented: "I am excited about the collaboration agreement and look forward to
having such a strong partner focusing on the treatment of asthma and chronic
obstructive pulmonary disease. The collaboration creates a momentum for
Easyhaler products in Europe and strengthens Orion's strategic objective to
become a stronger player in the field of respiratory medication."
Guido Oelkers, Executive Vice President Commercial Operations, Nycomed,
commented: "We are very pleased to have signed this collaboration agreement with
Orion. We see great potential in these high quality Easyhaler products in major
European countries and the MENA region. They will significantly enhance
Nycomed's fast-growing Respiratory portfolio."
About Easyhaler®
Orion's portfolio of proprietary products includes Easyhaler®, an in-house
developed dry-powder inhaler. Orion has developed Easyhaler-adapted dry powder
formulations of several well-known generic active substances (salbutamol,
beclometasone, budesonide, formoterol) used in the treatment of asthma and
COPD. At the moment under development are new combined formulations of
budesonide-formoterol, and fluticasone-salmeterol for the treatment of asthma
and COPD.
About Orion
Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.
The Group's net sales in 2010 amounted to approximately EUR 850 million. The
Company invested EUR 85 million in research and development. At the end of
2010, the Group had a total of approximately 3,100 employees, of whom 2,450
worked in Finland and 650 in other countries. Orion's A and B shares are listed
on NASDAQ OMX Helsinki. For more information visit:www.orion.fi/en
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified
portfolio focused on branded medicines in gastroenterology, respiratory and
inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC
products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in
emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more
than 100 countries. It has strong platforms in Europe and in fast-growing
markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US
and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of
? 3.2 billion in 2010 and an adjusted EBITDA of ? 851 million.
For more information visitwww.nycomed.com
For further information
Media:
Tobias Cottmann, phone: +41 44 555 15 10
Jonathan Birt, Financial Dynamics, phone: +44 75 155 97 858
Investors:
Christian B. Seidelin, phone: +41 44 555 11 04
Orion Corporation:
Dr. Liisa Hurme, Senior Vice President, Proprietary Products
phone: +358 50 966 2874
This press release has been issued by Nycomed International Management GmbH,
Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
--- End of Message ---
Nycomed
Thurgauerstrasse 130 Glattpark-Opfikon Switzerland
Press Release Orion Corporation DE:
http://hugin.info/144179/R/1536150/468652.pdf
Press Release Orion Corporation EN:
http://hugin.info/144179/R/1536150/468651.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nycomed via Thomson Reuters ONE
[HUG#1536150]
Unternehmensinformation / Kurzprofil:
Datum: 04.08.2011 - 08:59 Uhr
Sprache: Deutsch
News-ID 56975
Anzahl Zeichen: 7621
contact information:
Town:
Glattpark-Opfikon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 175 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD"
steht unter der journalistisch-redaktionellen Verantwortung von
Nycomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
